Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug ...

U.S. President Donald Trump directed his health department on Tuesday to work with Congress on revamping a law that allows ...

PARIS (Reuters) -Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, ...

Dr. Scott Gottlieb, former FDA commissioner and Pfizer board member, warned that proposed tariffs on pharmaceutical imports could destabilize the U.S. generic drug supply. In an interview with CNBC, ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

The drugmaker said it would stop studying danuglipron after a participant in one of its trials experienced a possible ...

Danuglipron was the latest drug investors were hinging hope on to enter the obesity market.